PMN310 is an experimental treatment being developed by ProMIS Neurosciences to treat Alzheimer’s disease.

How PMN310 works

Alzheimer’s disease is a neurodegenerative disorder associated with the formation of clumps or aggregates of a protein called amyloid beta. These clumps are toxic to nerve cells and contribute to the progression of the disease. Once aggregates begin to form, they can provide a scaffold for even larger aggregates to form from amyloid beta monomers, or units.

PMN310 is an antibody that binds to the neurotoxic amyloid beta aggregates, preventing additional amyloid beta monomers from adding to them. Therefore, PMN310 may potentially neutralize toxic aggregates and prevent neurodegeneration.

PMN310 research

The neuroprotective effect of PMN310 was investigated in mouse models of Alzheimer’s disease.

Researchers injected forms of amyloid beta into the brains of the mice to simulate Alzheimer’s disease. The injected amyloid beta formed aggregates, which caused a dementia-like neurological deficit in the animals.

This was demonstrated using a memory-behavior test called object recognition. Normal mice exposed to an object remember it when they see it a second time and do not pause to study it for as long. Mice with induced amyloid beta damage lost the ability to discriminate between familiar and new objects, and spent similar amounts of time exploring both objects.

After being treated with PMN310, the mice returned to normal behavior, distinguishing between new and known objects in their explorations.

Based on these observations, the researchers concluded that PMN310 may work to prevent the short-term memory loss caused by toxic amyloid beta aggregates.

Other information

ProMIS has two other lead products that could potentially treat Alzheimer’s disease, PMN330 and PMN350, which target different areas on toxic amyloid beta aggregates.

***

Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
×
Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Latest Posts
    The User does not have any posts